Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 301, Issue 4, 2011, Pages

  Baraboi, Elena Dana ^a   St Pierre, David H ^a   Shooner, Julie ^a   Timofeeva, Elena ^a   Richard, Denis ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

c fos; Hypothalamic pituitary axis; Refeeding; Subdiaphragmatic vagotomy

Indexed keywords

EXENDIN 4; MESSENGER RNA; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANOREXIA; ARCUATE NUCLEUS; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; GLUCOSE METABOLISM; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIMBIC CORTEX; MAGNOCELLULAR NUCLEUS; MALE; NODOSE GANGLION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUPRAOPTIC NUCLEUS; VAGOTOMY; VAGUS NERVE;

ANIMALS; BRAIN; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHALAMUS; MALE; MODELS, ANIMAL; NODOSE GANGLION; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PEPTIDES; PITUITARY-ADRENAL SYSTEM; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; RECEPTORS, GLUCAGON; VAGUS NERVE; VENOMS;

EID: 80053631384     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00424.2010     Document Type: Article

References (58)

1. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044: 127-131, 2005.
2. Aziz A, Anderson GH, Giacca A, Cho F. Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: a possible role for dietary peptides. Am J Physiol Regul Integr Comp Physiol 289: R688-R694, 2005.
3. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127: 546-558, 2004.
4. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53: 2492-2500, 2004.
5. Baraboi ED, Smith P, Ferguson AV, Richard D. Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. Am J Physiol Regul Integr Comp Physiol 298: R1098-R1110, 2010.
6. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol Endocrinol Metab 266: E459-E466, 1994.
7. Batsell WR, Best MR. One bottle too many? Method of testing determines the detection of overshadowing and retention of taste aversions. Animal Learn Behav 21: 154-158, 1993.
8. Baumgartner I, Pacheco-Lopez G, Ruttimann EB, Arnold M, Asarian L, Langhans W, Geary N, Hillebrand JJ. Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats. J Neuroendocrinol 22: 557-563, 2010.
9. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092-1100, 2005.
10. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon- derived peptides. Nat Clin Pract Endocrinol Metab 1: 22-31, 2005.
11. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267: 7402-7405, 1992.
12. Galaverna OG, Seeley RJ, Berridge KC, Grill HJ, Epstein AN, Schulkin J. Lesions of the central nucleus of the amygdala. I: Effects on taste reactivity, taste aversion learning and sodium appetite. Behav Brain Res 59: 11-17, 1993.
13. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9 -39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268: 19650-19655, 1993.
14. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7: 2294-2300, 1995.
15. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 102: 81-86, 2001.
16. Grigson PS, Reilly S, Shimura T, Norgren R. Ibotenic acid lesions of the parabrachial nucleus and conditioned taste aversion: further evidence for an associative deficit in rats. Behav Neurosci 112: 160-171, 1998.
17. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44: 81-86, 1999.
18. Hayes UL, Chambers KC. High doses of vasopressin delay the onset of extinction and strengthen acquisition of LiCl-induced conditioned taste avoidance. Physiol Behav 84: 625-633, 2005.
19. Herbert H, Moga MM, Saper CB. Connections of the parabrachial nucleus with the nucleus of the solitary tract and the medullary reticular formation in the rat. J Comp Neurol 293: 540-580, 1990.
20. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 273: G920-G927, 1997.
21. Kolligs F, Fehmann HC, Goke R, Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9 -39) amide. Diabetes 44: 16-19, 1995.
22. Lacroix S, Vallieres L, Rivest S. C-fos mRNA pattern and corticotropinreleasing factor neuronal activity throughout the brain of rats injected centrally with a prostaglandin of E2 type. J Neuroimmunol 70: 163-179, 1996.
23. Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 128: 97-107, 2005.
24. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138: 4445-4455, 1997.
25. Louis-Sylvestre J. Validation of tests of completeness of vagotomy in rats. J Auton Nerv Syst 9: 301-314, 1983.
26. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 30: 1332-1340, 2006.
27. Malendowicz LK, Neri G, Nussdorfer GG, Nowak KW, Zyterska A, Ziolkowska A. Prolonged exendin-4 administration stimulates pituitaryadrenocortical axis of normal and streptozotocin-induced diabetic rats. Int J Mol Med 12: 593-596, 2003.
28. Malendowicz LK, Nussdorfer GG, Nowak KW, Ziolkowska A, Tortorella C, Trejter M. Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: investigations into the mechanism(s) underlying Ex4 effect. Int J Mol Med 12: 237-241, 2003.
29. Malendowicz LK, Spinazzi R, Nussdorfer GG, Trejter M. Effects of preproglucagon-derived peptides and exendins on steroid-hormone secretion from dispersed adrenocortical cells of normal and streptozotocininduced diabetic rats. Int J Mol Med 12: 115-119, 2003.
30. Martin JR, Rogers RC, Novin D. Excessive gastric retention by vagotomized rats and rabbits given a solid diet. Bull Psychonom Soc 10: 291-294, 1977.
31. Mordes JP, el Lozy M, Herrera MG, Silen W. Effects of vagotomy with and without pyloroplasty on weight and food intake in rats. Am J Physiol Regul Integr Comp Physiol 236: R61-R66, 1979.
32. Morgan JI, Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 14: 421-451, 1991.
33. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744, 1993.
34. Navarro M, Rodriquez de Fonseca F, Alvarez E, Chowen JA, Zueco JA, Gomez R, Eng J, Blazquez E. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67: 1982-1991, 1996.
35. Peters CT, Choi YH, Brubaker PL, Anderson GH. A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutrient selection by rats. J Nutr 131: 2164-2170, 2001.
36. Ritter S, McGlone JJ, Kelley KW. Absence of lithium-induced taste aversion after area postrema lesion. Brain Res 201: 501-506, 1980.
37. Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gomez R, Munoz RM, Eng J, Blazquez E. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49: 709-717, 2000.
38. Rowland NE, Crews EC, Gentry RM. Comparison of Fos induced in rat brain by GLP-1 and amylin. Regul Pept 71: 171-174, 1997.
39. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150: 1174-1181, 2009.
40. Sagar SM, Sharp FR, Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240: 1328-1331, 1988.
41. Saper CB. Central autonomic system. In: The Rat Nervous System (2nd ed.), edited by Paxinos G. New York: Academic, 1995, p. 107-135.
42. Sarkar S, Fekete C, Legradi G, Lechan RM. Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropinreleasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 985: 163-168, 2003.
43. Seo S, Ju S, Chung H, Lee D, Park S. Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr J 55: 867-874, 2008.
44. Simmons DM, Arriza JL, Swanson LW. A complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radiolabeled single-stranded RNA probes. J Histotechnol 12: 169-181, 1989.
45. St Andre J, Reilly S. Effects of central and basolateral amygdala lesions on conditioned taste aversion and latent inhibition. Behav Neurosci 121: 90-99, 2007.
46. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146: 3748-3756, 2005.
47. Tauchi M, Zhang R, D'Alessio DA, Seeley RJ, Herman JP. Role of central glucagon-like peptide-1 in hypothalamo-pituitary-adrenocortical facilitation following chronic stress. Exp Neurol 210: 458-466, 2008.
48. Timofeeva E, Baraboi ED, Richard D. Contribution of the vagus nerve and lamina terminalis to brain activation induced by refeeding. Eur J Neurosci 22: 1489-1501, 2005
49. Timofeeva E, Huang Q, Richard D. Effects of treadmill running on brain activation and the corticotropin-releasing hormone system. Neuroendocrinology 77: 388-405, 2003.
50. Timofeeva E, Picard F, Duclos M, Deshaies Y, Richard D. Neuronal activation and corticotropin-releasing hormone expression in the brain of obese (fa/fa) and lean (fa/?) Zucker rats in response to refeeding. Eur J Neurosci 15: 1013-1029, 2002.
51. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72, 1996.
52. Verbalis JG, McHale CM, Gardiner TW, Stricker EM. Oxytocin and vasopressin secretion in response to stimuli producing learned taste aversions in rats. Behav Neurosci 100: 466-475, 1986.
53. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40: 597-601, 1997.
54. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 55: 3387-3393, 2006.
55. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110: 43-52, 2002.
56. Yamamoto T. Brain regions responsible for the expression of conditioned taste aversion in rats. Chem Senses 32: 105-109, 2007.
57. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48: 1026-1034, 1999.
58. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21: 1125-1135, 2003.